Blockchain Registration Transaction Record

Theriva Biologics Receives Rare Pediatric Drug Designation from FDA for Treatment of Retinoblastoma

Theriva Biologics receives Rare Pediatric Drug Designation for VCN-01, a treatment for retinoblastoma, from the FDA. This signifies an important step forward in addressing the high unmet need for effective treatments for childhood cancer.

This news matters as it highlights the urgent need for new treatment options for pediatric patients with retinoblastoma, a rare and challenging condition. The Rare Pediatric Drug Designation for VCN-01 signifies an important step forward in addressing the high unmet need for effective treatments for childhood cancer. The growing market size for retinoblastoma treatment also indicates the increasing industry resonance and potential social benefit.